MarketResearchReportTrends

  According to MRFR analysis, Global   Remdesivir Market   is expected to register a   CAGR of 7.90 %  during the forecast period of 2023 to 2032 and reach   USD 10.90 Billion by 2032. The global pharmaceutical landscape has been significantly impacted by the emergence of Remdesivir, a broad-spectrum antiviral medication that gained prominence during the COVID-19 pandemic. Initially developed to combat Ebola, Remdesivir found renewed relevance as a potential treatment for severe cases of COVID-19. This shift in focus has led to a dynamic and rapidly evolving Remdesivir market, where demand, production, and research continue to shape its trajectory. Remdesivir, developed by Gilead Sciences, garnered attention for its antiviral properties early on. It inhibits the replication of viruses by disrupting the RNA synthesis process, making it a promising candidate for a range of viral infections. The drug gained emergency use authorization for  COVID-19 treatm...

Remdesivir Market Remdesivir is an antiviral drug. FDA approved the remdesivir drug in April 2020 for the clinical trials for COVID 19 treatment. Studies have shown that around 46% of US patients have been recovered from COVID 19 quickly. The growth of the global Remdesivir (COVID 19 )  market can be contributed to the growing need for rescue medication, including remdesivir drugs, due to the outbreak of COVID-19 globally. Furthermore, the rising geriatric population is also expected to fuel market growth during the forecast period. However, the availability of various substitutes for Remdesivir (COVID 19 ) , are expected to restrain the growth of the global Remdesivir (COVID 19 )  market. According to MRFR analysis, Global Remdesivir Market is expected to register a CAGR of 7.90 % during the forecast period of 2020 to 2030 and reach USD 9.88 Billion by 2030. Gilead Sciences, Inc., Bright Gene, Hainan Haiyao, Cipla, Pfizer, Merck, Cayman Chemical, Kelun Pharma, Hunan ...